Old and new acetylcholinesterase inhibitors for Alzheimer’s disease
The DOI matches its Crossref record; 26 of the 27 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: To date, pharmacological treatment of Alzheimer's disease (AD) includes Acetylcholinesterase Inhibitors (AChEIs) for mild-to-moderate AD, and memantine for moderate-to-severe AD. AChEIs reversibly inhibit acetylcholinesterase (AChE), thus increasing the availability of acetylcholine in cholinergic synapses, enhancing cholinergic transmission. These drugs provide symptomatic short-term benefits, without clearly counteracting the progression of the disease. AREAS COVERED: On the wake of successful clinical trials which lead to the marketing of AChEIs donepezil, rivastigmine and galantamine, many compounds with AChEI properties have been developed and tested mainly in Phase I-II clinical trials in the last twenty years. Here, we review clinical trials initiated and interrupted, and those ongoing so far. EXPERT OPINION: Despite many clinical trials with novel AChEIs have been carried out after the registration of those currently used to treat mild to moderate AD, none so far has been successful in a Phase III trial and marketed. Alzheimer's disease is a complex multifactorial disorder, therefore therapy should likely address not only the cholinergic system but also additional neurotransmitters. Moreover, such treatments should be started in very mild phases of the disease, and preventive strategies addressed in elderly people.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Traditional AD drugs (Fig. 5) are categorized into two classes: AChEIs (tacrine (3), donepezil (4), rivastigmine (5), galantamine (6)) and NMDA receptor antagonists (memantine (7)).396”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [396]
Citations
Cites
Doody, R. S., Gavrilova, S. I., Sano, M., Thomas, R. G., Aisen, P. S., Bachurin, S. O., Seely, L., & Hung, D. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61074-0 · Cited by 460 · cited 1×
“Dimebon was safe, well tolerated, and showed significant benefits in ADAS-cog [9].”
BackgroundMedhurst, A. D., Atkins, A. R., Beresford, I. J., Brackenborough, K., Briggs, M. A., Calver, A. R., Cilia, J., Cluderay, J. E., Crook, B., Davis, J. B., et al. (2007) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.120311 · Cited by 301 · cited 1×
“In mice and rats, inhibiting this receptor has been shown to enhance cholinergic signaling, reduce tau phosphorylation, and reverse behavioral deficits [22,23].”
BackgroundYang, G., Wang, Y., Tian, J., & Liu, J.-P. (2013) · PLoS ONE · doi:10.1371/journal.pone.0074916 · Cited by 241 · cited 2×
“their findings cautiously, due to the poor methodological quality of the trials included [7].”
BackgroundWeinreb, O., Amit, T., Bar-Am, O., & B.H. Youdim, M. (2012) · Current Drug Targets · doi:10.2174/138945012799499794 · Cited by 153 · cited 1×
“Finally, it possesses potent antiapoptotic and neuroprotective activities in vitro and in various neurodegenerative rat models (see [39] for review).”
BackgroundLin, C., Chen, P.-K., Chang, Y., Chuo, L.-J., Chen, Y.-S., Tsai, G. E., & Lane, H. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.08.010 · Cited by 143 · cited 1×
“D-amino acid oxidase inhibitor, gave promising results [55].”
BackgroundGrove, R., Harrington, C., Mahler, A., Beresford, I., Maruff, P., Lowy, M., Nicholls, A., Boardley, R., Berges, A., Nathan, P., et al. (2014) · Current Alzheimer Research · doi:10.2174/1567205010666131212110148 · Cited by 109
Huperzine A for Alzheimer's disease
Li, J., Wu, H. M., Zhou, R. L., Liu, G. J., & Dong, B. R. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005592.pub2 · Cited by 108
Lemes, L. F. N., Ramos, G. D. A., de Oliveira, A. S., da Silva, F. M. R., Couto, G. C., Boni, M. S., Guimarães, M. J. R., Souza, I. N. D. O., Bartolini, M., Andrisano, V., et al. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.12.024 · Cited by 100 · cited 1×
“A number of novel compounds have been synthesized and studied from a pharmacological and biochemical point of view or in mouse and rat models, including novel tacrine-related cholinesterase inhibitors [45], novel 7-aminoalkyl-substituted flavonoid derivatives [46], racemic benzochromenopyrimidinimines [47], Schiff bas…”
BackgroundA Randomized Study of H3 Antagonist ABT-288 in Mild-To-Moderate Alzheimer's Dementia1
Haig, G. M., Pritchett, Y., Meier, A., Othman, A. A., Hall, C., Gault, L. M., & Lenz, R. A. (2014) · Journal of Alzheimer's Disease · doi:10.3233/jad-140291 · Cited by 71 · cited 1×
“cally inferior to placebo but no statistical differences were detected [25].”
BackgroundNathan, P. J., Boardley, R., Scott, N. E., Berges, A., Maruff, P. T., Sivananthan, T., Upton, N., Lowy, M. T., Nestor, P. J., & Lai, R. Y. K. (2013) · Current Alzheimer Research · doi:10.2174/1567205011310030003 · Cited by 69 · cited 1×
“and had positive effects on tasks of attention and memory[17].”
Background
Research works printed but not linked: 2
- Birks J, 2006, Cochrane Database Syst Rev, 1, CD005593
- Abd Razik BM, 2016, Med Chem, 12
Cited by
Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138
Targeting Free Radicals in Oxidative Stress-Related Human Diseases
Poprac, P., Jomova, K., Simunkova, M., Kollar, V., Rhodes, C. J., & Valko, M. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.04.005 · Cited by 1,107
Savelieff, M. G., Nam, G., Kang, J., Lee, H. J., Lee, M., & Lim, M. H. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00138 · Cited by 581
Chalcone and its analogs: Therapeutic and diagnostic applications in Alzheimer’s disease
Thapa, P., Upadhyay, S. P., Suo, W. Z., Singh, V., Gurung, P., Lee, E. S., Sharma, R., & Sharma, M. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.104681 · Cited by 166
“Extensive research on drug discovery and development has led to FDA-approved drugs which include cholinesterase inhibitors such as donepezil (DPZ) [30–32], rivastigmine (RIV) [33–35], galantamine [36, 37], and a partial N -methyl-D-aspartate (NMDA) antagonist, Memantine[38] (Figure 3) [39].”
BackgroundMoss, D. E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21103438 · Cited by 146
“The current AChE inhibitors are far from adequate to meet the demand for highly effective AD interventions [81] that are urgently needed to improve cognitive functions and/or take advantage of the recently recognized additional anti-neurodegenerative benefits [54–62].”
Background
Metadata
- Authors
- Galimberti, D., & Scarpini, E.
- Affiliations
- University of Milan (IT)
- Corresponding author
- Galimberti, Daniela
- Venue
- Expert Opinion on Investigational Drugs
- Publisher
- Informa UK Limited
- Published
- 2016-08-05
- Volume
- 25
- Issue
- 10
- Pages
- 1181-1187
- ISSN
- 1354-3784 (ISSN-L)
- 1744-7658
- OpenAlex
- W2487848811
- Cited by
- 117
- References
- 27
- Citations by year
- 2026: 8 · 2025: 14 · 2024: 7 · 2023: 11 · 2022: 8 · 2021: 18 · 2020: 14 · 2019: 11 · 2018: 11 · 2017: 14 · 2016: 1
- FWCI
- 10.52
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Expert Opinion on Investigational Drugs (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- acetylcholinesterase inhibitors, Alzheimer's disease, donepezil, rivastigmine, galantamine, memantine, cholinergic neurotransmission, acetylcholine, clinical trials, drug development, early treatment, multifactorial therapy
- MeSH terms
- Acetylcholine, Aged, Alzheimer Disease, Animals, Cholinesterase Inhibitors, Humans, Severity of Illness Index, Drug Design, Treatment Outcome, Disease Progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Old and new acetylcholinesterase inhibitors for Alzheimer’s disease. https://app.cochat.ai/papers/10.1080/13543784.2016.1216972
- The paper
- Galimberti, D., & Scarpini, E. (2016). Old and new acetylcholinesterase inhibitors for Alzheimer’s disease. Expert Opinion on Investigational Drugs. https://doi.org/10.1080/13543784.2016.1216972
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.